SCHEMBL210786

SCHEMBL210786

O=[N+]([O-])c1ccc(N2CCOCC2)c(F)c1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.69
KMT2A Q03164 1/20 0.69
LMNA P02545 4/20 0.63
SMN1; SMN2 Q16637 3/20 0.61
SLC6A9 P48067 4/20 0.60
SLC6A5 Q9Y345 3/20 0.60
MAPT P10636 5/20 0.60
THRB P10828 1/20 0.60
CYP1A2 P05177 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
POLB P06746 1/20 0.56
HTT P42858 2/20 0.55
IDE P14735 1/20 0.55
RAB9A P51151 1/20 0.55
KDM4E B2RXH2 1/20 0.55
NPC1 O15118 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29723200 1.00 ALDH1A1 (0.69) ALDH1A1KMT2ALMNASMN1; SMN2SLC6A9
SCHEMBL5240348 0.96 ALDH1A1 (0.64) ALDH1A1KMT2ALMNASMN1; SMN2SLC6A9
SCHEMBL4379208 0.94 ALDH1A1 (0.63) ALDH1A1KMT2ALMNASMN1; SMN2SLC6A9
SCHEMBL5236073 0.92 ALDH1A1 (0.60) ALDH1A1KMT2ALMNASMN1; SMN2SLC6A9
SCHEMBL14464189 0.89 ALDH1A1 (0.79) ALDH1A1KMT2ALMNASMN1; SMN2SLC6A9
SCHEMBL30560071 0.88 ALDH1A1 (0.62) ALDH1A1KMT2ALMNASMN1; SMN2SLC6A9
SCHEMBL521191 0.88 ALDH1A1 (0.62) ALDH1A1KMT2ALMNASMN1; SMN2SLC6A9
SCHEMBL24267643 0.87 ALDH1A1 (0.57) ALDH1A1KMT2ALMNASMN1; SMN2SLC6A9
SCHEMBL4921368 0.86 ALDH1A1 (0.75) ALDH1A1KMT2ALMNASMN1; SMN2SLC6A9
SCHEMBL4163987 0.85 ALDH1A1 (0.66) ALDH1A1KMT2ALMNASMN1; SMN2SLC6A9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115389661-B Method for detecting genotoxic impurities in linezolid glucose injection 华润双鹤药业股份有限公司 2024-01-26 CN claimed
CN-115925647-A Production method of linezolid 湖北广济药业股份有限公司 2023-04-07 CN claimed
CN-115389661-A Method for detecting genotoxic impurities in linezolid glucose injection 华润双鹤药业股份有限公司 2022-11-25 CN claimed
CN-108339551-B Preparation method of novel antibacterial drug linezolid intermediate 扬州虹光生物科技有限公司 2021-05-28 CN claimed
EP-2563781-B1 PROCESSES FOR PREPARING LINEZOLID UNIV INDIANA RES & TECH CORP (US) 2016-10-26 EP claimed
EP-2563781-A1 PROCESSES FOR PREPARING LINEZOLID Indiana University Research and Technology Corporation (US) 2013-03-06 EP claimed
US-20130053557-A1 PROCESSES FOR PREPARING LINEZOLID INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2013-02-28 US claimed
WO-2011137222-A1 PROCESSES FOR PREPARING LINEZOLID INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2011-11-03 WO claimed
CN-1772750-A Prepn process of (R)-N-(3-fluoro-4-morpholinyl phenyl)-oxazolone-5-methyl alcohol UNIV ZHENGZHOU (CN) 2006-05-17 CN claimed
WO-2025054339-A1 TRIAZOLOPYRIDINE COMPOUNDS AS INHIBITORS OF KIT ARCUS BIOSCIENCES, INC. (US) 2025-03-13 WO disclosed
CN-118290358-A Method for preparing linezolid key intermediate (S) -5- ((benzylamino) methyl) oxazolidine-2-one 江苏医药职业学院 2024-07-05 CN disclosed
CN-117571871-A Method for separating and detecting linezolid starting material M1 and related impurities thereof 重庆华邦胜凯制药有限公司 2024-02-20 CN disclosed
CN-115389661-B Method for detecting genotoxic impurities in linezolid glucose injection 华润双鹤药业股份有限公司 2024-01-26 CN disclosed
CN-115389661-B Method for detecting genotoxic impurities in linezolid glucose injection 华润双鹤药业股份有限公司 2024-01-26 CN disclosed
WO-2002055013-A2 THERAPEUTIC CHROMONE COMPOUNDS ASTRAZENECA AB (SE) 2002-07-18 WO disclosed
EP-0717738-B1 SUBSTITUTED OXAZINE AND THIAZINE OXAZOLIDINONE ANTIMICROBIALS UPJOHN CO (US) 1999-10-20 EP disclosed
US-5880118-A Substituted oxazine and thiazine oxazolidinone antimicrobials PHARMACIA & UPJOHN COMPANY (US) 1999-03-09 US disclosed
US-5688792-A BACTERICIDES PHARMACIA & UPJOHN COMPANY (US) 1997-11-18 US disclosed
EP-0717738-A1 SUBSTITUTED OXAZINE AND THIAZINE OXAZOLIDINONE ANTIMICROBIALS PHARMACIA & UPJOHN COMPANY (US) 1996-06-26 EP disclosed
WO-1995007271-A1 SUBSTITUTED OXAZINE AND THIAZINE OXAZOLIDINONE ANTIMICROBIALS THE UPJOHN COMPANY (US) 1995-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053557-A1 PROCESSES FOR PREPARING LINEZOLID CYP2C9, CYP2C19, CYP3A43 ALDH1A1 703/4885KMT2A 958/4885LMNA 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.